Bionano Genomics (BNGO) Capital Leases (2021 - 2026)

Bionano Genomics has disclosed Capital Leases across 6 years of filings, most recently posting $3.5 million for Q1 2026.

• Capital Leases for Q1 2026 came in at $3.5 million, down 1.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 1.79% YoY), and the FY2025 annual result was $3.5 million, down 1.67% from the prior year.
• Capital Leases came in at $3.5 million for Q1 2026 at Bionano Genomics, roughly flat from $3.5 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $3.6 million in Q1 2022 to a low of $3.5 million in Q1 2026.
• The 5-year median for Capital Leases is $3.6 million (2024), against an average of $3.6 million.
• Across the five-year window, Capital Leases retreated 0.63% in 2022 and fell 1.79% in 2026, its largest moves.
• Bionano Genomics' Capital Leases stood at $3.6 million in 2022, then fell by 0.94% to $3.6 million in 2023, then fell by 1.28% to $3.5 million in 2024, then declined by 1.67% to $3.5 million in 2025, then fell by 0.49% to $3.5 million in 2026.
• The last three Capital Leases figures came in at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.